Current treatment guidelines for acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 8, 1998, Pages 2646-2652

  Melmed, Shlomo ^a,e   Jackson, Ivor ^b   Kleinberg, David ^c   Klibanski, Anne ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PERGOLIDE; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ACROMEGALY; ADVERSE DRUG REACTION; ARTICLE; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOTHERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; DOPAMINE AGONISTS; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 0031784539     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.8.2646     Document Type: Article

References (82)

1. Melmed S. 1990 Acromegaly. N Engl J Med. 322:966-977.
2. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71-79.
3. Bengtsson BA, Eden S, Ernest I, Oden A, Sjögren B. 1988 Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 223:327-335.
4. Ritchie CM, Atkinson AB, Kennedy AL, et al. 1990 Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J. 59:55-62.
5. Barkan AL. 1989 Acromegaly: diagnosis and therapy. Endocrinol Metab Clin North Am. 18:277-310.
6. Wright AD, Hill DM, Lowy C, Fraser TR. 1970 Mortality in acromegaly. Q J Med. 34:1-16.
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293-299.
8. Melmed S, Ho K, Klibanski A, Reichlin S, Thomer M. 1995 Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
9. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 301:1138-1142.
10. Rieu M, Kuhn J-M, Bricaire H, Luton J-P. 1984 Evaluation of treated acromegalic patients with normal growth hormone levels during oral glucose load. Acta Endocrinol (Copenh). 107:1-18.
11. Lee PDK, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Aguirre J. 1997 Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab. 82:2266-2274.
12. Isaksson OGP, Lindahl A, Nilsson A, Isgaard J. 1987 Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 8:426-438.
13. Spencer GSG, Hodgkinson SC, Bass JJ. 1991 Passive immunization against insulin-like growth factor-I does not inhibit growth hormone-stimulated growth of dwarf rats. Endocrinology. 128:2103-2109.
14. Molitch ME. 1992 Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 21:597-614.
15. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102.
16. Leiberman SA, Hoffman AR. 1990 Sequelae to acromegaly: reversibility with treatment of the primary disease. Horm Metab Res. 22:313-318.
17. Cheung NW, Taylor L, Boyages SC. 1997 An audit of long-term octreotide therapy for acromegaly. Aust NZ J Med. 27:12-18.
18. Grunstein RR, Ho KKY, Sullivan CE. 1994 Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 121:478-483.
19. Melmed S. 1996 Unwanted effects of growth hormone excess in the adult. J Pediatr Endocrinol Metab. 9:369-374.
20. Dobrashian RD, O'Halloran DJ, Hunt A, Beardwell CG, Shalet SM. 1993 Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol (Oxf). 38:589-593.
21. Chapman IM, Hartmann ML, Straue M, Johnson ML, Veldhuis JD, Thorner MO. 1994 Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab. 78:1312-1317.
22. Iranmanesh A, Grisso B, Veldhuis JD. 1994 Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 78:526-535.
23. Daughaday WH, Starkey RH, Saltman S, Gavin III JR, Mills-Dunlap B, Heath-Monnig E. 1987 Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab. 65:617-623.
24. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. 1995 Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab. 80:927-932.
25. van der Lely AJ. 1997 The role of radiotherapy in acromegaly. J Clin Endocrinal Metab. 82:3185-3186.
26. Lim MJ, Barkan AL, Buda AJ. 1992 Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 117:719-726.
27. Ross DA, Wilson CB. 1988 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 68:854-867.
28. Fahlbusch R, Honegger J, Schott W, Buchfelder M. 1994 Results of surgery in acromegaly. In: Wass JAH, ed. Treating acromegaly. Bristol: Journal of Endocrinology; 49-54.
29. Laws Jr ER, Carpenter SM, Scheithauer BW, Randall RV. 1987 Long-term results of transsphenoidal surgery for the management of acromegaly. In: Robbins R, Melmed S, eds. Acromegaly: a century of scientific and clinical progress. New York: Plenum Press; 241-248.
30. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. 1995 Depot long-acting somatostatin analog (Sandostatin-LAR) is effective treatment for acromegaly. J Clin Endocrinol Metab. 80:3267-3272.
31. Harris AG. 1996 Treatment of acromegaly. In: Daly AF, ed. Acromegaly and its management. Philadelphia: Lippincott-Raven; 49-68.
32. Barnard LB, Grantham WG, Lamberton P, O'Dorisio TM, Jackson IMD. 1986 Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med. 105:856-861.
33. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. 1985 The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 60:1161-1165.
34. Thuesen L, Christensen SE, Weeke J, Ørskov H, Henningsen P. 1989 The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf). 30:619-625.
35. Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, et al. 1991 Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest. 14:17-23.
36. Chanson P, Timsit J, Masquet C, et al. 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:921-925.
37. Musolino NR, Marino Jr R, Bronstein MD. 1990 Headache in acromegaly: dramatic improvement with the somatostatin analog SMS 201-995. Clin J Pain. 6:243-245.
38. Ezzat S, Snyder PJ, Young WF, et al. 1992 Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med. 117:711-718.
39. Newman B, Melmed S, Snyder PJ, et al. 1995 Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab. 80:2768-2775.
40. Sassolas G, Harris AG, James-Deidier A, French SMS, 201-995 Acromegaly Study Group. 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
41. Tauber JP, Babin TH, Tauber MT, et al. 1989 Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 68:917-924.
42. Roelfsema F, Frölich M, de Boer H, Harris AG. 1991 Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol (Copenh). 125:43-48.
43. James RA, White MC, Chatterjee S, Marciaj H, Kendall-Taylor P. 1992 A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly. Eur J Clin Invest. 22:554-561.
44. Fløgstad AK, Halse J, Haldorsen T, et al. 1995 Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab. 80:3601-3607.
45. Kaal A, Frystyk J, Skjærbaek C, et al. 1995 Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism. 44:6-14.
46. Lancranjan I, Bruns C, Grass P, et al. 1996 Sandostatin® LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 45:67-71.
47. Fløgstad AK, Halse J, Bakke S, et al. 1997 Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab. 82:23-28.
48. Gillis JC, Noble S, Goa KL. 1997 Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs. 53:681-699.
49. Giusti M, Gussoni G, Cuttica CM, Giordano G, Italian Multicenter Slow Release Lanreotide Study Group. 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab. 81:2089-2097.
50. Caron P, Morange-Ramos I, Cogne M, Jaquet P. 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 82:18-22.
51. Jaffe CA, Barkan AL. 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 21:713-735.
52. Besser GM, Wass JAH. 1978 Medical management of acromegaly with bromocriptine. Med J Aust. 2:31-33.
53. Vance ML, Evans WS, Thorner MB. 1984 Bromocriptine. Ann Intern Med. 100:78-91.
54. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomized study of SMS 201-995 vs. bromocriptine treatment in acromegaly clinical and biochemical effects. J Clin Endocrinol Metab. 70:1254-1261.
55. Fløgstad AK, Halse J, Grass P, et al. 1994 A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab. 79:461-465.
56. Colao A, Ferone D, Marzullo P, et al. 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 82:518-523.
57. Dunn PJ, Donald A, Espiner EA. 1977 Bromocriptine suppression of plasma growth hormone in acromegaly. Clin Endocrinol (Oxf). 7:273-281.
58. Pelkonen R, Ylikahri R, Karonen S-L. 1980 Bromocriptine treatment of patients with acromegaly resistant to conventional therapy. Clin Endocrinol (Oxf). 12:219-224.
59. Oppizzi G, Liuzzi A, Chiodini P, et al. 1984 Dopaminergic treatment of acromegalv different effects on hormone secretion and tumor size. J Clin Endocrinol Metab. 58:988-992.
60. Gross DJ, Halperin Y, Gomori JM, Glaser B. 1989 Bromocriptine treatment of acromegaly: possible dose dependency of the tumor size-reducing effect. Isr J Med Sci. 25:256-260.
61. Steinbeck K, Turtle JR. 1979 Treatment of acromegaly with bromocryptine. Aust NZ J Med. 9:217-224.
62. Scanlon MF. 1994 Dopamine agonists in the treatment of acromegaly. In: Wass JAH, ed. Treating acromegaly. Bristol: Journal of Endocrinology; 139-145.
63. Eastman RC, Gorden P, Roth J. 1979 Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab. 48:931-940.
64. Feek CM, McLelland J, Seth J, et al. 1984 How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol (Oxf). 20:401-408.
65. Kliman B, Kjellberg RN, Swisher B, Butler W. 1987 Long-term effects of proton beam therapy for acromegaly. In: Robbins RJ, Melmed S, eds. Acromegaly: a century of scientific and clinical progress. New York: Plenum Press; 221-228.
66. Speirs CJ, Reed PI, Morrison R, Aber V, Joplin GF. 1990 The effectiveness of external beam radiotherapy for acromegaly is not affected by previous pituitary ablative treatments. Acta Endocrinol (Copenh), 122:559-565.
67. Sheaves R. 1994 Pituitary irradiation for acromegaly. In: Wass JAH, ed. Treating acromegaly. Bristol: Journal of Endocrinology; 103-108.
68. Thorén M, Rähn T, Guo W-Y, Werner S. 1991 Stereotactic radiosurgery with the cobalt-60 gamma-unit in the treatment of growth hormone-producing pituitary tumors. Neurosurgery. 29:663-668.
69. Acromegaly Therapy Consensus Development Panel. 1994 Consensus statement: benefits vs. risks of medical therapy for acromegaly. Am J Med. 97:468-473.
70. Eastman RC, Gorden P, Glatstein E, Roth J. 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 21:693-712.
71. Barkan AL, Halasz I, Dornfeld KJ, et al. 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly J Clin Endocrinol Metab. 82:3187-3191.
72. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. 1986 Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 81:457-462.
73. Constine LS, Woolf PD, Cann D, et al. 1993 Hypothalamic-pituitary dysfunction after radiation for brain rumors. N Engl J Med. 328:87-94.
74. Brada M, Rajan B. 1994 The toxicity of radiotherapy in the treatment of pituitary adenoma. In: Wass JAH, ed. Treating acromegaly. Bristol: Journal of Endocrinology; 127-132.
75. Jones A. 1994 Complications of radiotherapy for acromegaly. In: Wass JAH, ed. Treating acromegaly. Bristol: Journal of Endocrinology; 115-125.
76. Ganz JC, Backlund EO, Thorsen FA. 1993 The effects of gamma knife surgery of pituitary adenomas on tumor growth and endocrinopathies. Sterotact Funct Neurosurg. 61:30-37.
77. Chiodini PG, Cozzi R, Dallabonzana D, et al. 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. 64:447-453.
78. Lamberts SWJ, Zweens M, Verschoor L, Del Pozo E. 1986 A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab. 63:16-19.
79. Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SWJ. 1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh). 125:637-642.
80. Sassolas G. 1995 Medical therapy with somatostatin analogues for acromegaly. Eur J Endocrinol. 133:675-677.
81. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ. 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem. 269:15892-15897.
82. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest. 100:2386-2392.